Potentialization of N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) cytotoxic activity by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in human ovarian cancer cells
Abstract
Objectives: TNF is one of the key cytokines involved in cancer development. TNF signaling can result in both stimulating and inhibitory signals that can result in opposite biological effects in cancerogenesis. 2-(1-adamantylamino)-6-methylpyridine (AdAMP) enhances TNF secretion whereas N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) is a NF-κB inhibitor potentially stimulating proapoptotic TNF signals. The aim of the study was to assess the effect of TPCK in combination with AdAMP on human ovarian cells.
Material and methods: CAOV-1 human ovarian cell line was incubated with TPCK and AdAMP for 24 hours. The cytotoxic effect was evaluated in a crystal violet assay. A monoclonal antibody against TNF, Infliximab, was added to examine the possible mechanism of interactions.
Results: Depending on concentration, AdAMP potentialized cytotoxic activity of TPCK or had a synergistic effect with TPCK. Infliximab did not reverse cytotoxicity of AdAMP and TPCK and in some cytotoxic and non-cytotoxic concentrations even enhanced their cytotoxicity.
Conclusions: AdAMP and TPCK cytotoxicity seems to be dependent on TNF signaling, however, the exact mechanism of interactions remains unclear.
Keywords: AdAMPTPCKTNFNF-kB inhibitorsproteasomeovarian cancercell line
References
- Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4): 765–781.
- Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011; 11(10): 719–725.
- Vargas-Hernández VM, Moreno-Eutimio MA, Acosta-Altamirano G, et al. Management of recurrent epithelial ovarian cancer. Gland Surg. 2014; 3(3): 198–202.
- Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007; 14(5): 195–208.
- Raja FA, Chopra N, Ledermann JA, et al. Targeted trials in ovarian cancer. Gynecol Oncol. 2010; 119(1): 151–156.
- Takeyama H, Wakamiya N, O'Hara C, et al. Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res. 1991; 51(16): 4476–4480.
- Ihnatko R, Kubes M. TNF signaling: early events and phosphorylation. Gen Physiol Biophys. 2007; 26(3): 159–167.
- MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal. 2002; 14(6): 477–492.
- Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002; 296(5573): 1634–1635.
- Kazimierczuk Z, Górska A, Switaj T, et al. Adamantylaminopyrimidines and -pyridines are potent inducers of tumor necrosis factor-alpha. Bioorg Med Chem Lett. 2001; 11(9): 1197–1200.
- Mauri JK, Lasek W, Górska A, et al. Synthesis, structure and tumour necrosis factor-alpha production-enhancing properties of novel adamantylamino heterocyclic derivatives. Anticancer Drug Des. 2001; 16(2-3): 73–80.
- Lasek W, Switaj T, Sieńko J, et al. Stimulation of TNF-alpha production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy. Cancer Chemother Pharmacol. 2002; 50(3): 213–222.
- Ferreira JJ, Rascol O. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Opin Neurol. 2000; 13(4): 431–436.
- Khare MD, Sharland M. Influenza. Expert Opin Pharmacother. 2000; 1(3): 367–375.
- Basarić N, Sohora M, Cindro N, et al. Antiproliferative and antiviral activity of three libraries of adamantane derivatives. Arch Pharm (Weinheim). 2014; 347(5): 334–340.
- Aggarwal S, Takada Y, Singh S, et al. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995; 270(42): 24995–25000.
- Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation. 1999; 100(12): 1330–1337.
- Gilmore TD, Koedood M, Piffat KA, et al. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene. 1996; 13(7): 1367–1378.
- Shames BD, Selzman CH, Meldrum DR, et al. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock. 1998; 10(6): 389–394.
- Voboril R, Weberova-Voborilova J. Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB. Neoplasma. 2007; 54(6): 495–502.
- Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101(6): 2377–2380.
- Kazimierczuk Z, Górska A, Switaj T, et al. Adamantylaminopyrimidines and -pyridines are potent inducers of tumor necrosis factor-alpha. Bioorg Med Chem Lett. 2001; 11(9): 1197–1200.
- Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2): 440–446.
- Knutson KL, Karyampudi L, Lamichhane P, et al. Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev. 2015; 34(1): 53–74.
- Pazhang Y, Jaliani HZ, Imani M, et al. Synergism between NF-kappa B inhibitor, celastrol, and XIAP inhibitor, embelin, in an acute myeloid leukemia cell line, HL-60. J Cancer Res Ther. 2016; 12(1): 155–160.
- Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995; 7(3): 251–259.
- Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001; 121(5): 1145–1157.
- Di Sabatino A, Pender SLF, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007; 133(1): 137–149.
- Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol. 1999; 19(6): 350–364.
